Delivery Order SPE2DB24D2205-SPE2DB25FDSTH

Award Date 10/16/24
Potential Completion Date 10/17/24
Potential Value $4.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,972.02 firm fixed-price delivery order is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a specialty medication. The contract has an ultimate completion date of June 27, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,146.73, is a delivery order for the product "PULMOZYME 1 MG/ML AMPUL 2.5ML" with a completion date of March 6, 2025. The contract is a firm fixed-price arrangement and does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $19,410.94, is a delivery order for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a specialized pharmaceutical product. The contract has an ultimate completion date of April 30, 2024 and is a firm fixed-price arrangement. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,054.69, is a Firm Fixed Price Delivery Order for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a specialty medication. The contract has an ultimate completion date of March 26, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,488.59 firm fixed-price delivery order is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a specialty medication. The contract has a completion date of December 9, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,849.28, is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product. The contract has a firm fixed price and is a delivery order, with a period of performance through November 29, 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that...
This federal contract award, issued by the Defense Logistics Agency (DLA), was made to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $57,367.38 firm fixed-price delivery order is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a specialty medication, to support military healthcare programs. The contract has an ultimate completion date of July 5, 2024. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $14,817.78, is for the delivery of Pulmozyme 1 mg/ml ampul 2.5 ml. This is a firm-fixed-price delivery order contract with an ultimate completion date of August 26, 2024. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Pulmozyme 1 mg/ml ampul 2.5 ml. The contract is a Delivery Order with a Firm Fixed Price of $25,335.45 and a period of performance through November 21, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,535.06 firm fixed-price delivery order is for the supply of Pulmozyme, a 1 mg/ml ampul medication. The contract has an ultimate completion date of December 12, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as a primary vehicle for...
  • SPE2DB24D2205
    Indefinite Delivery Contract
  • SPE2DB24D2205-SPE2DB25FDSTH
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,821.98 firm fixed-price delivery order is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product used in medical treatment. The contract has an ultimate completion date of October 17, 2024.

Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, covering similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies for military personnel, veterans, and other federal beneficiaries.

The contract award did not specify any set-aside requirements, indicating open competition.

Generated 1/15/25, 9:18 AM